This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) (STOP-HE)

This study has been completed.
Information provided by (Responsible Party):
Ocera Therapeutics Identifier:
First received: October 11, 2013
Last updated: February 16, 2017
Last verified: February 2017
The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.

Condition Intervention Phase
Acute Episode of Overt Hepatic Encephalopathy Hepatic Encephalopathy Drug: ornithine phenylacetate Drug: placebo intravenous infusion Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study

Resource links provided by NLM:

Further study details as provided by Ocera Therapeutics:

Primary Outcome Measures:
  • Change from Baseline in Hepatic Encephalopathy Stage [ Time Frame: Up to Study Day 19 ]

Secondary Outcome Measures:
  • Change from Baseline in Modified Orientation Log [ Time Frame: Up to Study Day 19 ]
  • Length of hospital stay [ Time Frame: Up to Study Day 19 ]

Other Outcome Measures:
  • Change from Baseline in Glasgow Coma Scale [ Time Frame: Up to Study Day 19 ]

Enrollment: 231
Study Start Date: November 2013
Study Completion Date: January 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ornithine phenylacetate
continuous intravenous infusion of ornithine phenylacetate for up to 5 days on top of standard of care
Drug: ornithine phenylacetate
dose levels predicated on level of hepatic decompensation
Other Name: OCR-002
Placebo Comparator: placebo intravenous infusion
continuous intravenous infusion of placebo up to 5 days on top of standard of care
Drug: placebo intravenous infusion
visually identical to active experimental
Other Name: 5% dextrose in water

Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled study of ornithine phenylacetate (OCR-002) administered intravenously to hospitalized patients with cirrhosis, hyperammonemia, and an acute episode of hepatic encephalopathy administered on top of standard of care treatment.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
  • Elevated venous ammonia

Exclusion Criteria:

  • Renal failure with serum creatinine > 3 mg/dL or need for dialysis
  • Molecular Adsorbent Recirculation System utilized
  • Pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01966419

  Show 132 Study Locations
Sponsors and Collaborators
Ocera Therapeutics
Study Chair: Stan Bukofzer, M.D. Ocera Therapeutics, Inc.
  More Information

Responsible Party: Ocera Therapeutics Identifier: NCT01966419     History of Changes
Other Study ID Numbers: OCR002-HE209
Study First Received: October 11, 2013
Last Updated: February 16, 2017

Keywords provided by Ocera Therapeutics:
hepatic encephalopathy
ornithine phenylacetate

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Pathologic Processes
Phenylacetic acid
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on September 21, 2017